Genetic Polymorphism of CYP2C9 Among Sistani Ethnic Group in Gorgan

Marjani, Abdoljalal; Gharanjik, Aman Mohammad

doi:10.1007/s12291-017-0660-7

Cited by 8 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Albanians, Romani and Macedonians, CYP2D6 variants do not differ from other European populations [82]. CYP2C9 allele and genotype variation in the Sistani ethnic group from Gorgan, South East of Caspian Sea and North East of Iran, shows important differences when compared to other populations (CYP2C9*1/*1, 53.9%; CYP2C9*1/*2, 22.1%; CYP2C9*1/*3, 11.4%; CYP2C9*2/*2, 2.9%; CYP2C9*2/*3, 4.3%; CYP2C9*3/*3, 0%) [83].…”

Section: Ethnic Differences In Adrsmentioning

confidence: 93%

Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions

Cacabelos

Naidoo

Corzo

et al. 2021

IJMS

View full text Add to dashboard Cite

Adverse drug reactions (ADRs) rank as one of the top 10 leading causes of death and illness in developed countries. ADRs show differential features depending upon genotype, age, sex, race, pathology, drug category, route of administration, and drug–drug interactions. Pharmacogenomics (PGx) provides the physician effective clues for optimizing drug efficacy and safety in major problems of health such as cardiovascular disease and associated disorders, cancer and brain disorders. Important aspects to be considered are also the impact of immunopharmacogenomics in cutaneous ADRs as well as the influence of genomic factors associated with COVID-19 and vaccination strategies. Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting. The implementation of PGx requires: (i) education of physicians and all other parties involved in the use and benefits of PGx; (ii) prospective studies to demonstrate the benefits of PGx genotyping; (iii) standardization of PGx procedures and development of clinical guidelines; (iv) NGS and microarrays to cover genes with high PGx potential; and (v) new regulations for PGx-related drug development and PGx drug labelling.

show abstract

Section: Ethnic Differences In Adrsmentioning

confidence: 93%

Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions

Cacabelos

Naidoo

Corzo

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…on Caucasians populations, they exposed that the CYP2C9*2 and CYP2C9*3 were more allele frequent comparing to African American and Asian populations while Chinese and Japanese have not showed the CYP2C9*2 allele . The allele frequencies of CYP2C9 differ among different populations and many investigates on CYP2C9 variation in different populations have revealed a significant difference in alleles and genotypes frequency [17,18] . This may be the reason behind the probable ethnic differences to drug response.…”

Section: Cyp2c9 Variants Genotypementioning

confidence: 99%

“…The differences in genotype of enzyme have displayed the association of certain genotypes with a great risk of s-warfarin over bleeding events and anticoagulation in comparing to a wild type . Clinical studies have also suggested that subject with the mutated genotypes require lower doses of S-warfarin (10-20% and/or 20-50%) when compared to a wild type subject [17]…”

Section: Cyp2c9 Variants Genotypementioning

confidence: 99%

Genotype Frequency of Cytochrome P450 2C9 (CYP2C9) Mutations in Iraqi Ethnic Groups

Suhad R. AL- Tayie,

Salwa Jaber Al-Awadi,

Iqbal harbi Mohammed Al-Zaidi

2021

Indian Journal of Forensic Medicine & Toxicology

View full text Add to dashboard Cite

In Middle East, There is a little knowledge about the cytochrome P450s genotyping and there has not found any investigation about the CYP2C9 allelic diversity in Iraqi population nowadays .CYP2C9 genotypes were established in a total of 400 subjects of healthy Iraqis volunteers from different areas in Iraq (Arab ,Kurd and Turkmen). After extraction of DNA from blood cells and polymerase chain reaction, SNP genotyping for CYP2C9 variants (2,3,4 and 5) was performed by using the primer extension KASP® genotyping assay. The agreement with "Hardy-Weinberg equilibrium" for detected the distribution of CYP2C9 genotype was proved by (X 2 -test) .The CYP2C9*2 , CYP2C9*3 and CYP2C9*5 alleles variant were identified in Iraqi population , whereas the CYP2C9*4 was absent , The results revealed that there was non-significant association observed in all CYP2C9 genotypes among Iraqi ethnic groups .then The CYP2C9 genotypes results in our study were compared to other populations and The results exhibited that the frequency of Iraqi population CYP2C9 variants were comparable with other countries and ethnic groups. This is the first report of CYP2C9 variants from Iraq; the results are assist as a database on CYP2C9 gene polymorphisms and clinical data baseline for dosing and avoiding adverse reactions of drugs metabolized by CYP2C9 in Iraqis patients.

show abstract

“…Hence, acquiring precise information on the (Ataby et al, 2013;Azarpira et al, 2010;Hosseinkhani et al, 2018;Marjani and Gharanjik, 2018;Namazi et al, 2010;Razavi et al, 2017;Tabari et al, 2015;Zand et al, 2007). Ultimately, Fars people possess highest CYP2C9*2 and CYP2C9*3 allele frequencies of 24.34% and 9.8%, respectively.…”

Section: Ppi Pharmacogenomics (With Emphasize On Iran)mentioning

confidence: 99%

Proton pump inhibitors in Iranian population: from clinical regimens to pharmacogenomics

et al. 2020

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) are one of the highly prescribed or over-the-counter available medications among Iranians, mainly to treat conditions such as helicobacter pylori infection, gastroesophageal reflux disease or frequent heartburn. In recent years, several reports have shown potential adverse effects of PPI administration among which cardiovascular adverse events, myocardial infarction and chronic kidney disease are considered as the greatest risks. Recent addition of proton pump inhibitors to the list of medications on Beers Criteria of Potentially Inappropriate Drugs has arisen significant concerns about their safety. This review aims at providing an up-to date overview of PPIs indications and their pharmacogenomics and pharmacokinetics in Iranian population. The focus of this review is on PPIs regimens in Iranian population and then it is compared with the reported studies performed on other ethnic groups around the world. An extensive review of the literature was carried out and data under various sections were identified using a computerized literature search via Pubmed, Web of Science, Google Scholar and some local search engines. All abstracts and full text articles were examined and most relevant papers were selected for inclusion in this review. Also several expert internalists were interviewed for their clinical experiences in this field.

show abstract

Genetic Polymorphism of CYP2C9 Among Sistani Ethnic Group in Gorgan

Cited by 8 publications

References 38 publications

Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions

Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions

Genotype Frequency of Cytochrome P450 2C9 (CYP2C9) Mutations in Iraqi Ethnic Groups

Proton pump inhibitors in Iranian population: from clinical regimens to pharmacogenomics

Contact Info

Product

Resources

About